Glioblastoma
📧 Sign up to get email alerts when something new happens for Glioblastoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma [Phase 2]
Phase 2 clinical trial update for newly diagnosed glioblastoma evaluating adjuvant temozolomide with optional 5-aminolevulinic acid and low-…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody for Recurrent Malignant Glioma [Phase 1]
This is a Phase 1 clinical trial evaluating IL13Rα2 CAR-T cells that secrete anti-PD-L1 antibody for recurrent malignant glioma; the study i…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) [Phase 1, Phase 2]
This clinical trial update covers a Phase 1/2 study evaluating INO-5401 and INO-9012 delivered by electroporation with cemiplimab in newly d…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications [Phase 1, Phase 2]
Clinical trial update for PLX038 in primary CNS tumors with MYC or MYCN amplification; Phase 1/2 studies are currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies [Phase 1]
Phase 1 clinical trial evaluating RSC-1255 in patients with advanced malignancies carrying RAS mutations, sponsored by RasCal Therapeutics, …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers
This clinical trial update describes a study on communication among physicians, patients, and caregivers in glioblastoma and brain cancer ca…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma [Phase 1]
Phase 1 clinical trial evaluating dual-targeting CAR-NK cells for recurrent or progressive glioblastoma and high-grade glioma is currently r…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Early Phase Study of KESONOTIDE™in Participants With Solid Tumours [Phase 1, Phase 2]
KESONOTIDE is being studied in an early-phase (Phase 1/Phase 2) trial for solid tumours and is currently recruiting across multiple cancer i…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors [Phase 1]
Phase 1 clinical trial evaluating ONC206 for newly diagnosed and recurrent diffuse midline gliomas and other recurrent malignant CNS tumors;…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma [Phase 2]
A Phase 2 clinical trial is testing daily temozolomide in elderly patients with newly diagnosed glioblastoma and unmethylated MGMT promoter;…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. [Phase 1]
A Phase 1 dose-finding study of Lu-177 DOTATATE for glioblastoma evaluating combination with standard of care in newly diagnosed disease and…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells [Phase 1]
Phase 1 clinical trial update for E-SYNC, a CAR T cell therapy using a synNotch EGFRvIII trigger to drive anti-EphA2/IL-13Ralpha2 CAR expres…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Impact of Androgen Signaling on the Composition of the Immune Microenvironment in Glioblastomas [NA]
This clinical trial update explores how androgen signaling influences the immune cell composition within glioblastoma tumors; the study is c…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas [Phase 1]
A Phase 1 clinical trial evaluating the combination of BGB-290 with temozolomide in patients with IDH1/IDH2-mutant gliomas, including gliobl…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Neuromodulation-Induced Cortical Prehabilitation in High Grade Glioma Near the Motor Pathway: Cortical Plasticity Assessed by Navigated Transcranial Magnetic Stimulation (nTMS) [NA]
A clinical trial evaluating neuromodulation to prehabilitate cortical function in patients with high-grade glioma near motor pathways, using…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma [Phase 3]
Phase 3 trial EF-41/KEYNOTE D58 evaluating Optune with temozolomide and pembrolizumab for newly diagnosed glioblastoma is currently recruiti…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma [Phase 2]
A Phase 2 clinical trial is evaluating the safety and efficacy of Pumitamig (BNT327) in patients with recurrent glioblastoma; recruitment is…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion [EARLY_Phase 1]
A Phase 1 study assessing lorlatinib for newly diagnosed high-grade gliomas with ALK or ROS1 fusions; currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma [Phase 1]
A Phase 1 trial evaluating the addition of AZD1390 to radiation therapy for newly diagnosed pediatric high-grade gliomas, including diffuse …
-
CLINICAL_TRIALS research · 2026-03-11Clinical Trial Update: Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma [Phase 1]
Clinical trial update for a Phase 1 study of a personalized neoantigen DNA vaccine in combination with retifanlimab PD-1 blockade for newly …
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Glioblastoma Radiotherapy Using IMRT or Proton Beams [NA]
A clinical trial is recruiting to compare radiotherapy approaches—intensity-modulated radiotherapy (IMRT) and proton beam therapy—for gliobl…
-
CLINICAL_TRIALS research · 2026-03-10Clinical Trial Update: Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients [Phase 3]
A Phase 3 clinical trial is planned to evaluate advanced imaging techniques for evaluating the tumor immune microenvironment in glioblastoma…
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac [Phase 1]
Phase 1 clinical trial exploring safe intensification of hypofractionated glioblastoma treatment on an MR-Linac; currently not yet recruitin…
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients [EARLY_Phase 1]
AZD1390 is being studied in an early-phase trial for recurrent and newly diagnosed WHO grade 4 gliomas (glioblastoma/high-grade glioma), wit…
-
CLINICAL_TRIALS research · 2026-03-09Clinical Trial Update: RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM) [Phase 1]
Phase 1 study evaluating RNA-Lipid Particle vaccines for recurrent glioblastoma; the trial is currently active but not recruiting.